Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakamura

Showing results (621-630 of 709) with videos related to

Pageof 71
Sort By:
Scientific Reports|August 28, 2023
Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injuryTakayuki Kondo, Kentaro Fujimoto, Kisako Fujiwara, et al.
Oncology Letters|August 13, 2020
Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancerYushi Imai, Tetsuhiro Chiba, Takayuki Kondo, et al.
Molecular Cancer Therapeutics|October 3, 2018
Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal CancerYu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, et al.
Circulation. Cardiovascular Interventions|March 16, 2019
Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical PresentationTullio Palmerini, Antonio G Bruno, Martine Gilard, et al.
Heart and Vessels|January 1, 2022
Relationship between platelet aggregation and stroke risk after percutaneous coronary intervention: a PENDULUM analysisYuji Matsumaru, Takanari Kitazono, Kazushige Kadota, et al.
Biochemical Pharmacology|February 27, 2025
MEGF6 knockdown ameliorates lenvatinib-induced muscle differentiation suppression and enhances the antitumor effect of lenvatinib on hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.
Cancer Biology & Therapy|April 23, 2016
Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancerYu Sunakawa, Dongyun Yang, Miriana Moran, et al.
Cancer Science|February 6, 2021
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancerShin Takahashi, Yasuhiro Sakamoto, Tadamichi Denda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinomaTakuya Yonemoto, Sadahisa Ogasawara, Naoya Kanogawa, et al.
International Journal of Cardiology|March 21, 2025
Cumulative plaque burden analysis for phenotyping epicardial coronary artery diseaseTsung-Ying Tsai, Pruthvi C Revaiah, Ali Aldujeli, et al.
Pageof 71

Showing results (621-630 of 709) with videos related to

Sort By:
Pageof 71
Scientific Reports|August 28, 2023
Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injuryTakayuki Kondo, Kentaro Fujimoto, Kisako Fujiwara, et al.
Oncology Letters|August 13, 2020
Interferon-γ induced PD-L1 expression and soluble PD-L1 production in gastric cancerYushi Imai, Tetsuhiro Chiba, Takayuki Kondo, et al.
Molecular Cancer Therapeutics|October 3, 2018
Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal CancerYu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, et al.
Circulation. Cardiovascular Interventions|March 16, 2019
Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical PresentationTullio Palmerini, Antonio G Bruno, Martine Gilard, et al.
Heart and Vessels|January 1, 2022
Relationship between platelet aggregation and stroke risk after percutaneous coronary intervention: a PENDULUM analysisYuji Matsumaru, Takanari Kitazono, Kazushige Kadota, et al.
Biochemical Pharmacology|February 27, 2025
MEGF6 knockdown ameliorates lenvatinib-induced muscle differentiation suppression and enhances the antitumor effect of lenvatinib on hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.
Cancer Biology & Therapy|April 23, 2016
Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancerYu Sunakawa, Dongyun Yang, Miriana Moran, et al.
Cancer Science|February 6, 2021
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancerShin Takahashi, Yasuhiro Sakamoto, Tadamichi Denda, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinomaTakuya Yonemoto, Sadahisa Ogasawara, Naoya Kanogawa, et al.
International Journal of Cardiology|March 21, 2025
Cumulative plaque burden analysis for phenotyping epicardial coronary artery diseaseTsung-Ying Tsai, Pruthvi C Revaiah, Ali Aldujeli, et al.
Pageof 71